SlideShare a Scribd company logo
1 of 13
Download to read offline
+
+
Therapeutic Principles
 The management of GCTs is governed by the potential for
rapid growth and for cure in essentially all patients;
 This translates into a need for rapid diagnosis and staging and
expeditious application of appropriate treatment so as not to
have patients die unnecessarily or experience side effects from
treatment that would not have been required with earlier
diagnosis and proper management.
 After orchiectomy, staging imaging studies, serum tumor
marker status should be performed and treatment plans should
be developed as rapidly as can be reasonably accomplished.
+
 The probability of cure even in the presence of metastatic
disease has led to an aggressive approach with regard to the
administration of chemotherapy and the performance of
surgery after chemotherapy to resect residual masses
 Chemotherapy is generally administered regardless of low
white blood cell counts or thrombocytopenia, and nephrotoxic
chemotherapy (cisplatin) is often administered even in the
presence of moderate to severe renal insufficiency.
+
 Similarly, an aggressive surgical approach is taken to resect all
sites of residual disease after chemotherapy for NSGCT even if
this involves multiple anatomic sites.
 The young age and generally good health of patients with
GCTs permits an aggressive treatment approach if needed.
+
 Serum tumor markers strongly influence the management of
GCTs, particularly NSGCTs.
 As discussed, elevated serum AFP or hCG after orchiectomy
indicates the presence of metastatic disease, and these patients
are preferentially given chemotherapy.
 For patients receiving chemotherapy, increasing serum tumor
marker levels during or after therapy generally indicate refractory
or relapsed disease, respectively.
 As discussed earlier, serum AFP, hCG, and LDH levels at the
initiation of chemotherapy are important prognostic factors and
influence the selection and duration of chemotherapy regimens.
+
 Testis cancer is a relatively rare disease, and general urologist
and general oncologists do not typically treat a large volume of
patients with GCTs. In addition, the treatment algorithms are
complex and nuanced, and the data supporting certain treatments,
such as RPLND, are based on data from a relatively small number
of surgeons who have performed a large number of these
operations
 Most urology residents in the United States complete their training
having performed two or fewer RPLND procedures.
 Several studies reported improved survival when the treatment
was provided at high-volume institutions .
 Whenever possible, patients with GCTs should be treated at high-
volume centers, and RPLND should be performed by surgeons
who are experienced with this operation.
+
Contrasting Seminoma and
Nonseminoma Germ Cell Tumor
 For treatment purposes, the distinction between seminoma and NSGCT is very important.
 Compared with NSGCT, seminoma has a more favorable natural history. In general,
seminoma tends to be less aggressive, to be diagnosed at an earlier stage, and to spread
predictably along lymphatic channels to the retroperitoneum before spreading
hematogenously to the lungs or other organs. At diagnosis, the proportion of patients with
CS I, II, and III disease is 85%, 10%, and 5% for seminoma and approximately 33%, 33%,
and 33% for NSGCT (Powles et al, 2005).
 Seminoma is also associated with a lower incidence of occult metastasis among patients
with CS I (10% to 15% vs. 25% to 35% for NSGCT) and a lower risk of systemic relapse
after treatment of the retroperitoneum (1% to 4% after radiotherapy for seminoma vs. 10%
after RPLND for NSGCT), which has important implications for the use of chemotherapy.
 Seminoma is less likely to have elevated serum tumor markers, and serum tumor markers
do not range as high as in NSGCT.
 Also, serum tumor markers are not used in the IGCCCG risk classification of seminoma.
+
 Compared with NSGCT, seminoma is exquisitely sensitive to
radiation therapy and platin-based chemotherapy.
 Substantially lower radiation doses are required to eradicate
seminoma compared with other solid tumors
 Radiation therapy is a standard treatment option for CS I, IIA, and
IIB seminoma but has no role in NSGCT, with the exception of
treatment for brain metastases.
 Seminoma accounts for only 10% of advanced GCT cases despite
the fact that it accounts for 52% to 56% of all GCTs.
 A poor prognosis IGCCCG risk category does not exist for
advanced seminoma, and greater than 90% of metastatic cases
are classified as good risk (compared with 56% for NSGCT)
(International Germ Cell Consensus Classification, 1997.
+
 The risk of teratoma at metastatic sites is generally not a
consideration for advanced seminoma, which has important
implications for the management of residual masses after
chemotherapy.
 However, the potential for seminoma to transform into NSGCT
elements is an important consideration in the management of
patients who fail to respond to chemotherapy or who relapse after
radiation therapy.
 Of patients with metastatic seminoma who relapse after treatment,
approximately 10% to 15% have NSGCT elements at the site of
relapse.
 An autopsy study showed that 30% of patients who die of
seminoma have NSGCT elements at metastatic sites
+
 Because GCTs are almost always cured, numerous clinical trials
have been conducted in an attempt to minimize treatment and
avoid unnecessary therapies in an effort to reduce short-term and
particularly long-term side effects and toxicity.
 One approach has been to limit the number of patients who
receive two interventions (“double therapy”): either surgery or
chemotherapy and not both.
 However, because NSGCTs are usually mixed tumors, and
teratoma often exists at metastatic sites with other GCT elements,
“cure” often requires chemotherapy to kill the chemosensitive
components and surgery to remove teratomatous components.
+
Intratubular Germ Cell Neoplasia
 ITGCN is diagnosed by
 testicular biopsy performed for the investigation of infertility,
 contralateral testis biopsy in patients with GCT, or
 within the affected testis in a patient undergoing testis-sparing surgery.
 The rationale for treatment of ITGCN is based on the high risk of
developing invasive GCT; 50% risk of developing an invasive GCT
within 5 years.
 Treatment options include
 Orchiectomy,
 low-dose radiotherapy, and
 close observation.
+
 The choice of therapy should be individualized based on
 the patient’s desire for future paternity,
 the presence or absence of a normal contralateral testis, and
 the patient’s desire to avoid testosterone replacement therapy.
 Radical orchiectomy is the most definitive treatment, although low-dose
radiotherapy (≥20 Gy) is associated with similar rates of local control with
the prospect of preserving testicular endocrine function owing to the
relative radioresistance of Leydig cells compared with germinal epithelium.
 However, testosterone replacement therapy is ultimately required in up to
40% of patients, and patients should be monitored after radiotherapy for
adequate testicular androgen production.
 To preserve testicular endocrine function, dose reductions to less than 20
Gy have been investigated, but cases of recurrent ITGCN have been
observed
+
 For patients with a normal contralateral testis who desire future
paternity, radical orchiectomy is preferred because scatter to the
contralateral testis from radiotherapy may impair
spermatogenesis.
 For patients with abnormal semen parameters but sufficient for
assisted reproductive techniques, close surveillance with periodic
ultrasound evaluation of the testis is a reasonable strategy with
deferred therapy until successful pregnancy and/or development
of GCT.
 Another option for these patients is testis exploration, sperm
harvesting, and cryopreservation for assisted reproductive
techniques and radical orchiectomy followed by testosterone
replacement therapy

More Related Content

What's hot

diagnosis and outline of management of localized prostate cancer for non-urol...
diagnosis and outline of management of localized prostate cancer for non-urol...diagnosis and outline of management of localized prostate cancer for non-urol...
diagnosis and outline of management of localized prostate cancer for non-urol...Dr Mayank Mohan Agarwal
 
Locally Advanced Carcinoma Prostate
Locally Advanced Carcinoma ProstateLocally Advanced Carcinoma Prostate
Locally Advanced Carcinoma ProstateSasikumar Sambasivam
 
Incidentaloma adrenal
Incidentaloma adrenalIncidentaloma adrenal
Incidentaloma adrenalPraveen Ganji
 
Prostate carcinoma- diagnosis and staging
Prostate  carcinoma- diagnosis and stagingProstate  carcinoma- diagnosis and staging
Prostate carcinoma- diagnosis and stagingGovtRoyapettahHospit
 
MANAGEMENT OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY & RADIATION ...
MANAGEMENT OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY & RADIATION ...MANAGEMENT OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY & RADIATION ...
MANAGEMENT OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY & RADIATION ...GAURAV NAHAR
 
Management of Non Muscle Invasive Bladder Cancer
Management of Non Muscle Invasive Bladder CancerManagement of Non Muscle Invasive Bladder Cancer
Management of Non Muscle Invasive Bladder CancerDr.Bhavin Vadodariya
 
Focussed therapy and imaging in prostate cancer
Focussed therapy and imaging in prostate cancerFocussed therapy and imaging in prostate cancer
Focussed therapy and imaging in prostate cancerPrateek Laddha
 
Journal club TACE vs SBRT in Hepatocellular carcinoma
Journal club TACE vs SBRT in Hepatocellular carcinomaJournal club TACE vs SBRT in Hepatocellular carcinoma
Journal club TACE vs SBRT in Hepatocellular carcinomaAnil Gupta
 
Prostate cancer 2018: A brief overview
Prostate cancer 2018: A brief overviewProstate cancer 2018: A brief overview
Prostate cancer 2018: A brief overviewZeena Nackerdien
 
Prostate cancer , radiotherapy
Prostate cancer , radiotherapyProstate cancer , radiotherapy
Prostate cancer , radiotherapyMohammad Ashour
 
Carcinoma of the prostate
Carcinoma of the prostateCarcinoma of the prostate
Carcinoma of the prostateOsman Altohamy
 
Management of Prostate Cancer
Management of Prostate CancerManagement of Prostate Cancer
Management of Prostate CancerZeena Nackerdien
 
Prostate carcinoma- etiopathogenesis
Prostate  carcinoma- etiopathogenesisProstate  carcinoma- etiopathogenesis
Prostate carcinoma- etiopathogenesisGovtRoyapettahHospit
 

What's hot (20)

diagnosis and outline of management of localized prostate cancer for non-urol...
diagnosis and outline of management of localized prostate cancer for non-urol...diagnosis and outline of management of localized prostate cancer for non-urol...
diagnosis and outline of management of localized prostate cancer for non-urol...
 
Locally Advanced Carcinoma Prostate
Locally Advanced Carcinoma ProstateLocally Advanced Carcinoma Prostate
Locally Advanced Carcinoma Prostate
 
Incidentaloma adrenal
Incidentaloma adrenalIncidentaloma adrenal
Incidentaloma adrenal
 
Prostate carcinoma- diagnosis and staging
Prostate  carcinoma- diagnosis and stagingProstate  carcinoma- diagnosis and staging
Prostate carcinoma- diagnosis and staging
 
Carcinoma of Prostate
Carcinoma of ProstateCarcinoma of Prostate
Carcinoma of Prostate
 
Prostate cancer
Prostate cancerProstate cancer
Prostate cancer
 
Cancer of Unknown Primary
Cancer of Unknown PrimaryCancer of Unknown Primary
Cancer of Unknown Primary
 
MANAGEMENT OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY & RADIATION ...
MANAGEMENT OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY & RADIATION ...MANAGEMENT OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY & RADIATION ...
MANAGEMENT OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY & RADIATION ...
 
Management of Non Muscle Invasive Bladder Cancer
Management of Non Muscle Invasive Bladder CancerManagement of Non Muscle Invasive Bladder Cancer
Management of Non Muscle Invasive Bladder Cancer
 
Ca prostate
Ca prostateCa prostate
Ca prostate
 
Focussed therapy and imaging in prostate cancer
Focussed therapy and imaging in prostate cancerFocussed therapy and imaging in prostate cancer
Focussed therapy and imaging in prostate cancer
 
Management of Rectal Carcinoma
Management of Rectal Carcinoma Management of Rectal Carcinoma
Management of Rectal Carcinoma
 
Journal club TACE vs SBRT in Hepatocellular carcinoma
Journal club TACE vs SBRT in Hepatocellular carcinomaJournal club TACE vs SBRT in Hepatocellular carcinoma
Journal club TACE vs SBRT in Hepatocellular carcinoma
 
carcinoma prostate
carcinoma prostatecarcinoma prostate
carcinoma prostate
 
Carcinoma prostate
Carcinoma prostateCarcinoma prostate
Carcinoma prostate
 
Prostate cancer 2018: A brief overview
Prostate cancer 2018: A brief overviewProstate cancer 2018: A brief overview
Prostate cancer 2018: A brief overview
 
Prostate cancer , radiotherapy
Prostate cancer , radiotherapyProstate cancer , radiotherapy
Prostate cancer , radiotherapy
 
Carcinoma of the prostate
Carcinoma of the prostateCarcinoma of the prostate
Carcinoma of the prostate
 
Management of Prostate Cancer
Management of Prostate CancerManagement of Prostate Cancer
Management of Prostate Cancer
 
Prostate carcinoma- etiopathogenesis
Prostate  carcinoma- etiopathogenesisProstate  carcinoma- etiopathogenesis
Prostate carcinoma- etiopathogenesis
 

Similar to Testicular tumors treatment

Management of patients with primary colorectal cancer and
Management of patients with primary colorectal cancer andManagement of patients with primary colorectal cancer and
Management of patients with primary colorectal cancer andYuvaraj Karthick
 
bladder preservation - Bladder Cancer .pptx
bladder preservation - Bladder Cancer .pptxbladder preservation - Bladder Cancer .pptx
bladder preservation - Bladder Cancer .pptxshipragupta140193
 
Terminal illness care
Terminal illness careTerminal illness care
Terminal illness careMohammad Asif
 
Allogeineic Stem Cell Transplantation for adult acute lymphoblastic leukemia:...
Allogeineic Stem Cell Transplantation for adult acute lymphoblastic leukemia:...Allogeineic Stem Cell Transplantation for adult acute lymphoblastic leukemia:...
Allogeineic Stem Cell Transplantation for adult acute lymphoblastic leukemia:...raditio ghifiardi
 
Management of HCC, an update
Management of HCC, an updateManagement of HCC, an update
Management of HCC, an updateMohammed A Suwaid
 
Bladder preservation in carcinoma of bladder
Bladder preservation in carcinoma of bladderBladder preservation in carcinoma of bladder
Bladder preservation in carcinoma of bladderBright Singh
 
Oral Cancers chemo & RT.pptx
Oral Cancers chemo & RT.pptxOral Cancers chemo & RT.pptx
Oral Cancers chemo & RT.pptxAtulGupta369
 
Aml and bone marrow transplant
Aml and bone marrow transplantAml and bone marrow transplant
Aml and bone marrow transplantJoydeep Ghosh
 
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer  BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer European School of Oncology
 
Renal cell carcinoma ( RCC )ADJUVANT TRIALS.pptx
Renal cell carcinoma ( RCC )ADJUVANT TRIALS.pptxRenal cell carcinoma ( RCC )ADJUVANT TRIALS.pptx
Renal cell carcinoma ( RCC )ADJUVANT TRIALS.pptxAnandHosalli
 
Metastatic renal cell carcinoma
Metastatic renal cell carcinomaMetastatic renal cell carcinoma
Metastatic renal cell carcinomaHarshaR35
 
lapc-170421131858.pdf
lapc-170421131858.pdflapc-170421131858.pdf
lapc-170421131858.pdfYahya Tfeil
 
ADJUVANT RADIATION IN CA GALLBLADDER
ADJUVANT RADIATION IN CA GALLBLADDERADJUVANT RADIATION IN CA GALLBLADDER
ADJUVANT RADIATION IN CA GALLBLADDERMUNEER khalam
 
Initial chemotherapy and radiation for pancreatic cancer
Initial chemotherapy and radiation for pancreatic cancerInitial chemotherapy and radiation for pancreatic cancer
Initial chemotherapy and radiation for pancreatic cancerDr Tauqeer A Siddiqui MD FACP
 
Grey zone colorectal liver metastasis
Grey zone colorectal liver metastasisGrey zone colorectal liver metastasis
Grey zone colorectal liver metastasisSujan Shrestha
 
Highlights in the treatment of Rectal cancer.pptx
Highlights in the treatment of Rectal cancer.pptxHighlights in the treatment of Rectal cancer.pptx
Highlights in the treatment of Rectal cancer.pptxMona Quenawy
 

Similar to Testicular tumors treatment (20)

Management of patients with primary colorectal cancer and
Management of patients with primary colorectal cancer andManagement of patients with primary colorectal cancer and
Management of patients with primary colorectal cancer and
 
bladder preservation - Bladder Cancer .pptx
bladder preservation - Bladder Cancer .pptxbladder preservation - Bladder Cancer .pptx
bladder preservation - Bladder Cancer .pptx
 
Git j club eso cancer metastatic trts.
Git j club eso cancer metastatic trts.Git j club eso cancer metastatic trts.
Git j club eso cancer metastatic trts.
 
Terminal illness care
Terminal illness careTerminal illness care
Terminal illness care
 
Anal Cancer
Anal CancerAnal Cancer
Anal Cancer
 
Allogeineic Stem Cell Transplantation for adult acute lymphoblastic leukemia:...
Allogeineic Stem Cell Transplantation for adult acute lymphoblastic leukemia:...Allogeineic Stem Cell Transplantation for adult acute lymphoblastic leukemia:...
Allogeineic Stem Cell Transplantation for adult acute lymphoblastic leukemia:...
 
Management of HCC, an update
Management of HCC, an updateManagement of HCC, an update
Management of HCC, an update
 
Bladder preservation in carcinoma of bladder
Bladder preservation in carcinoma of bladderBladder preservation in carcinoma of bladder
Bladder preservation in carcinoma of bladder
 
Oral Cancers chemo & RT.pptx
Oral Cancers chemo & RT.pptxOral Cancers chemo & RT.pptx
Oral Cancers chemo & RT.pptx
 
A complete gallbladder cancer review.pptx
A complete gallbladder cancer review.pptxA complete gallbladder cancer review.pptx
A complete gallbladder cancer review.pptx
 
Aml and bone marrow transplant
Aml and bone marrow transplantAml and bone marrow transplant
Aml and bone marrow transplant
 
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer  BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
BALKAN MCO 2011 - D. Vrbanec - Adjuvant chemotherapy of colorectal cancer
 
Renal cell carcinoma ( RCC )ADJUVANT TRIALS.pptx
Renal cell carcinoma ( RCC )ADJUVANT TRIALS.pptxRenal cell carcinoma ( RCC )ADJUVANT TRIALS.pptx
Renal cell carcinoma ( RCC )ADJUVANT TRIALS.pptx
 
Metastatic renal cell carcinoma
Metastatic renal cell carcinomaMetastatic renal cell carcinoma
Metastatic renal cell carcinoma
 
Rectal cancer
Rectal cancer Rectal cancer
Rectal cancer
 
lapc-170421131858.pdf
lapc-170421131858.pdflapc-170421131858.pdf
lapc-170421131858.pdf
 
ADJUVANT RADIATION IN CA GALLBLADDER
ADJUVANT RADIATION IN CA GALLBLADDERADJUVANT RADIATION IN CA GALLBLADDER
ADJUVANT RADIATION IN CA GALLBLADDER
 
Initial chemotherapy and radiation for pancreatic cancer
Initial chemotherapy and radiation for pancreatic cancerInitial chemotherapy and radiation for pancreatic cancer
Initial chemotherapy and radiation for pancreatic cancer
 
Grey zone colorectal liver metastasis
Grey zone colorectal liver metastasisGrey zone colorectal liver metastasis
Grey zone colorectal liver metastasis
 
Highlights in the treatment of Rectal cancer.pptx
Highlights in the treatment of Rectal cancer.pptxHighlights in the treatment of Rectal cancer.pptx
Highlights in the treatment of Rectal cancer.pptx
 

More from Praveen Ganji

Study designs & amp; trials presentation1 2
Study designs & amp; trials presentation1 2Study designs & amp; trials presentation1 2
Study designs & amp; trials presentation1 2Praveen Ganji
 
Nccn prostate presentation1
Nccn prostate presentation1Nccn prostate presentation1
Nccn prostate presentation1Praveen Ganji
 
Metabolic evaluation of urinary lithiasis 2
Metabolic evaluation of urinary lithiasis 2Metabolic evaluation of urinary lithiasis 2
Metabolic evaluation of urinary lithiasis 2Praveen Ganji
 
Surgically correctable hypertension
Surgically correctable hypertensionSurgically correctable hypertension
Surgically correctable hypertensionPraveen Ganji
 
Perinatal hdn f recovered file 1
Perinatal hdn f recovered file 1 Perinatal hdn f recovered file 1
Perinatal hdn f recovered file 1 Praveen Ganji
 
Pheo presentation 3 2 18
Pheo presentation 3 2 18Pheo presentation 3 2 18
Pheo presentation 3 2 18Praveen Ganji
 
Urodynamic studies (1)
Urodynamic studies (1)Urodynamic studies (1)
Urodynamic studies (1)Praveen Ganji
 

More from Praveen Ganji (11)

Rcc1
Rcc1Rcc1
Rcc1
 
Study designs & amp; trials presentation1 2
Study designs & amp; trials presentation1 2Study designs & amp; trials presentation1 2
Study designs & amp; trials presentation1 2
 
Nccn prostate presentation1
Nccn prostate presentation1Nccn prostate presentation1
Nccn prostate presentation1
 
Metabolic evaluation of urinary lithiasis 2
Metabolic evaluation of urinary lithiasis 2Metabolic evaluation of urinary lithiasis 2
Metabolic evaluation of urinary lithiasis 2
 
Surgically correctable hypertension
Surgically correctable hypertensionSurgically correctable hypertension
Surgically correctable hypertension
 
Endo bph
Endo bphEndo bph
Endo bph
 
Ln in ca penis
Ln in ca penisLn in ca penis
Ln in ca penis
 
Perinatal hdn f recovered file 1
Perinatal hdn f recovered file 1 Perinatal hdn f recovered file 1
Perinatal hdn f recovered file 1
 
Dtpa in pujo
Dtpa in pujoDtpa in pujo
Dtpa in pujo
 
Pheo presentation 3 2 18
Pheo presentation 3 2 18Pheo presentation 3 2 18
Pheo presentation 3 2 18
 
Urodynamic studies (1)
Urodynamic studies (1)Urodynamic studies (1)
Urodynamic studies (1)
 

Recently uploaded

SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdfHongBiThi1
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptxNIKITA BHUTE
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 

Recently uploaded (20)

SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...American College of physicians ACP high value care recommendations in rheumat...
American College of physicians ACP high value care recommendations in rheumat...
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdfSGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA    .pdf
SGK NGẠT NƯỚC ĐHYHN RẤT LÀ HAY NHA .pdf
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptxORAL HYPOGLYCAEMIC AGENTS  - PART 2.pptx
ORAL HYPOGLYCAEMIC AGENTS - PART 2.pptx
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 

Testicular tumors treatment

  • 1. +
  • 2. + Therapeutic Principles  The management of GCTs is governed by the potential for rapid growth and for cure in essentially all patients;  This translates into a need for rapid diagnosis and staging and expeditious application of appropriate treatment so as not to have patients die unnecessarily or experience side effects from treatment that would not have been required with earlier diagnosis and proper management.  After orchiectomy, staging imaging studies, serum tumor marker status should be performed and treatment plans should be developed as rapidly as can be reasonably accomplished.
  • 3. +  The probability of cure even in the presence of metastatic disease has led to an aggressive approach with regard to the administration of chemotherapy and the performance of surgery after chemotherapy to resect residual masses  Chemotherapy is generally administered regardless of low white blood cell counts or thrombocytopenia, and nephrotoxic chemotherapy (cisplatin) is often administered even in the presence of moderate to severe renal insufficiency.
  • 4. +  Similarly, an aggressive surgical approach is taken to resect all sites of residual disease after chemotherapy for NSGCT even if this involves multiple anatomic sites.  The young age and generally good health of patients with GCTs permits an aggressive treatment approach if needed.
  • 5. +  Serum tumor markers strongly influence the management of GCTs, particularly NSGCTs.  As discussed, elevated serum AFP or hCG after orchiectomy indicates the presence of metastatic disease, and these patients are preferentially given chemotherapy.  For patients receiving chemotherapy, increasing serum tumor marker levels during or after therapy generally indicate refractory or relapsed disease, respectively.  As discussed earlier, serum AFP, hCG, and LDH levels at the initiation of chemotherapy are important prognostic factors and influence the selection and duration of chemotherapy regimens.
  • 6. +  Testis cancer is a relatively rare disease, and general urologist and general oncologists do not typically treat a large volume of patients with GCTs. In addition, the treatment algorithms are complex and nuanced, and the data supporting certain treatments, such as RPLND, are based on data from a relatively small number of surgeons who have performed a large number of these operations  Most urology residents in the United States complete their training having performed two or fewer RPLND procedures.  Several studies reported improved survival when the treatment was provided at high-volume institutions .  Whenever possible, patients with GCTs should be treated at high- volume centers, and RPLND should be performed by surgeons who are experienced with this operation.
  • 7. + Contrasting Seminoma and Nonseminoma Germ Cell Tumor  For treatment purposes, the distinction between seminoma and NSGCT is very important.  Compared with NSGCT, seminoma has a more favorable natural history. In general, seminoma tends to be less aggressive, to be diagnosed at an earlier stage, and to spread predictably along lymphatic channels to the retroperitoneum before spreading hematogenously to the lungs or other organs. At diagnosis, the proportion of patients with CS I, II, and III disease is 85%, 10%, and 5% for seminoma and approximately 33%, 33%, and 33% for NSGCT (Powles et al, 2005).  Seminoma is also associated with a lower incidence of occult metastasis among patients with CS I (10% to 15% vs. 25% to 35% for NSGCT) and a lower risk of systemic relapse after treatment of the retroperitoneum (1% to 4% after radiotherapy for seminoma vs. 10% after RPLND for NSGCT), which has important implications for the use of chemotherapy.  Seminoma is less likely to have elevated serum tumor markers, and serum tumor markers do not range as high as in NSGCT.  Also, serum tumor markers are not used in the IGCCCG risk classification of seminoma.
  • 8. +  Compared with NSGCT, seminoma is exquisitely sensitive to radiation therapy and platin-based chemotherapy.  Substantially lower radiation doses are required to eradicate seminoma compared with other solid tumors  Radiation therapy is a standard treatment option for CS I, IIA, and IIB seminoma but has no role in NSGCT, with the exception of treatment for brain metastases.  Seminoma accounts for only 10% of advanced GCT cases despite the fact that it accounts for 52% to 56% of all GCTs.  A poor prognosis IGCCCG risk category does not exist for advanced seminoma, and greater than 90% of metastatic cases are classified as good risk (compared with 56% for NSGCT) (International Germ Cell Consensus Classification, 1997.
  • 9. +  The risk of teratoma at metastatic sites is generally not a consideration for advanced seminoma, which has important implications for the management of residual masses after chemotherapy.  However, the potential for seminoma to transform into NSGCT elements is an important consideration in the management of patients who fail to respond to chemotherapy or who relapse after radiation therapy.  Of patients with metastatic seminoma who relapse after treatment, approximately 10% to 15% have NSGCT elements at the site of relapse.  An autopsy study showed that 30% of patients who die of seminoma have NSGCT elements at metastatic sites
  • 10. +  Because GCTs are almost always cured, numerous clinical trials have been conducted in an attempt to minimize treatment and avoid unnecessary therapies in an effort to reduce short-term and particularly long-term side effects and toxicity.  One approach has been to limit the number of patients who receive two interventions (“double therapy”): either surgery or chemotherapy and not both.  However, because NSGCTs are usually mixed tumors, and teratoma often exists at metastatic sites with other GCT elements, “cure” often requires chemotherapy to kill the chemosensitive components and surgery to remove teratomatous components.
  • 11. + Intratubular Germ Cell Neoplasia  ITGCN is diagnosed by  testicular biopsy performed for the investigation of infertility,  contralateral testis biopsy in patients with GCT, or  within the affected testis in a patient undergoing testis-sparing surgery.  The rationale for treatment of ITGCN is based on the high risk of developing invasive GCT; 50% risk of developing an invasive GCT within 5 years.  Treatment options include  Orchiectomy,  low-dose radiotherapy, and  close observation.
  • 12. +  The choice of therapy should be individualized based on  the patient’s desire for future paternity,  the presence or absence of a normal contralateral testis, and  the patient’s desire to avoid testosterone replacement therapy.  Radical orchiectomy is the most definitive treatment, although low-dose radiotherapy (≥20 Gy) is associated with similar rates of local control with the prospect of preserving testicular endocrine function owing to the relative radioresistance of Leydig cells compared with germinal epithelium.  However, testosterone replacement therapy is ultimately required in up to 40% of patients, and patients should be monitored after radiotherapy for adequate testicular androgen production.  To preserve testicular endocrine function, dose reductions to less than 20 Gy have been investigated, but cases of recurrent ITGCN have been observed
  • 13. +  For patients with a normal contralateral testis who desire future paternity, radical orchiectomy is preferred because scatter to the contralateral testis from radiotherapy may impair spermatogenesis.  For patients with abnormal semen parameters but sufficient for assisted reproductive techniques, close surveillance with periodic ultrasound evaluation of the testis is a reasonable strategy with deferred therapy until successful pregnancy and/or development of GCT.  Another option for these patients is testis exploration, sperm harvesting, and cryopreservation for assisted reproductive techniques and radical orchiectomy followed by testosterone replacement therapy